FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1579863504> ?p ?o ?g. }

• W1579863504 endingPage "345" @default.
• W1579863504 startingPage "341" @default.
• W1579863504 abstract "Object The presence of angiogenesis is a hallmark of glioblastoma (GBM). Vascular endothelial growth factor (VEGF), which drives angiogenesis, provides an additional target for conventional therapy. The authors conducted a prospective clinical trial to test the effectiveness of bevacizumab, an inhibitor of VEGF, in newly diagnosed GBM. Methods From 2006 through 2010, 51 eligible patients with newly diagnosed GBM were treated with involved-field radiation therapy and concomitant temozolomide (75 mg/m 2 daily for 42 days) along with bevacizumab (10 mg/kg every 2 weeks), starting 29 days after surgery. This was followed by 6 cycles of adjuvant temozolomide therapy (150 mg/m 2 on Days 1–7 of a 28-day cycle) with bevacizumab administered at 10 mg/kg on Days 8 and 22 of each 28-day cycle. Results The 6- and 12-month progression-free survival (PFS) rates were 85.1% and 51%, respectively. The 12- and 24-month overall survival (OS) rates were 85.1% and 42.5%, respectively. Grade III/IV toxicities were noted in 10 patients (19.6%). No treatment-related deaths were observed. Asymptomatic intracranial bleeding was noted in 5 patients. Conclusions The addition of bevacizumab to conventional therapy in newly diagnosed GBM appears to improve both PFS and OS in patients with newly diagnosed GBM, with acceptable morbidity. A shift toward diffuse relapse was noted in a significant number of patients. Ongoing Phase III clinical trials will show the true benefit of this antiangiogenic approach." @default.
• W1579863504 created "2016-06-24" @default.
• W1579863504 creator A5005752360 @default.
• W1579863504 creator A5015059017 @default.
• W1579863504 creator A5021588104 @default.
• W1579863504 creator A5026979469 @default.
• W1579863504 creator A5053284188 @default.
• W1579863504 creator A5062288892 @default.
• W1579863504 creator A5073119135 @default.
• W1579863504 creator A5078527574 @default.
• W1579863504 creator A5083922394 @default.
• W1579863504 date "2012-02-01" @default.
• W1579863504 modified "2023-09-27" @default.
• W1579863504 title "A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma" @default.
• W1579863504 cites W1603230122 @default.
• W1579863504 cites W1978041336 @default.
• W1579863504 cites W2002727873 @default.
• W1579863504 cites W2025702999 @default.
• W1579863504 cites W2032294682 @default.
• W1579863504 cites W2049332277 @default.
• W1579863504 cites W2054728198 @default.
• W1579863504 cites W2055832125 @default.
• W1579863504 cites W2064735785 @default.
• W1579863504 cites W2093783077 @default.
• W1579863504 cites W2096287682 @default.
• W1579863504 cites W2109134893 @default.
• W1579863504 cites W2130139391 @default.
• W1579863504 cites W2132697290 @default.
• W1579863504 cites W2157500906 @default.
• W1579863504 cites W2161216730 @default.
• W1579863504 cites W2162872529 @default.
• W1579863504 cites W2167923186 @default.
• W1579863504 cites W2170367762 @default.
• W1579863504 cites W2411180614 @default.
• W1579863504 doi "https://doi.org/10.3171/2011.9.jns11656" @default.
• W1579863504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22035272" @default.
• W1579863504 hasPublicationYear "2012" @default.
• W1579863504 type Work @default.
• W1579863504 sameAs 1579863504 @default.
• W1579863504 citedByCount "113" @default.
• W1579863504 countsByYear W15798635042012 @default.
• W1579863504 countsByYear W15798635042013 @default.
• W1579863504 countsByYear W15798635042014 @default.
• W1579863504 countsByYear W15798635042015 @default.
• W1579863504 countsByYear W15798635042016 @default.
• W1579863504 countsByYear W15798635042017 @default.
• W1579863504 countsByYear W15798635042018 @default.
• W1579863504 countsByYear W15798635042019 @default.
• W1579863504 countsByYear W15798635042020 @default.
• W1579863504 countsByYear W15798635042021 @default.
• W1579863504 countsByYear W15798635042022 @default.
• W1579863504 crossrefType "journal-article" @default.
• W1579863504 hasAuthorship W1579863504A5005752360 @default.
• W1579863504 hasAuthorship W1579863504A5015059017 @default.
• W1579863504 hasAuthorship W1579863504A5021588104 @default.
• W1579863504 hasAuthorship W1579863504A5026979469 @default.
• W1579863504 hasAuthorship W1579863504A5053284188 @default.
• W1579863504 hasAuthorship W1579863504A5062288892 @default.
• W1579863504 hasAuthorship W1579863504A5073119135 @default.
• W1579863504 hasAuthorship W1579863504A5078527574 @default.
• W1579863504 hasAuthorship W1579863504A5083922394 @default.
• W1579863504 hasConcept C126322002 @default.
• W1579863504 hasConcept C141071460 @default.
• W1579863504 hasConcept C143998085 @default.
• W1579863504 hasConcept C167734588 @default.
• W1579863504 hasConcept C2776056115 @default.
• W1579863504 hasConcept C2776694085 @default.
• W1579863504 hasConcept C2776755627 @default.
• W1579863504 hasConcept C2777025900 @default.
• W1579863504 hasConcept C2777389519 @default.
• W1579863504 hasConcept C2777802072 @default.
• W1579863504 hasConcept C2777910003 @default.
• W1579863504 hasConcept C2779384505 @default.
• W1579863504 hasConcept C2779429289 @default.
• W1579863504 hasConcept C2779434656 @default.
• W1579863504 hasConcept C2780394083 @default.
• W1579863504 hasConcept C2780739268 @default.
• W1579863504 hasConcept C509974204 @default.
• W1579863504 hasConcept C535046627 @default.
• W1579863504 hasConcept C71924100 @default.
• W1579863504 hasConcept C90924648 @default.
• W1579863504 hasConceptScore W1579863504C126322002 @default.
• W1579863504 hasConceptScore W1579863504C141071460 @default.
• W1579863504 hasConceptScore W1579863504C143998085 @default.
• W1579863504 hasConceptScore W1579863504C167734588 @default.
• W1579863504 hasConceptScore W1579863504C2776056115 @default.
• W1579863504 hasConceptScore W1579863504C2776694085 @default.
• W1579863504 hasConceptScore W1579863504C2776755627 @default.
• W1579863504 hasConceptScore W1579863504C2777025900 @default.
• W1579863504 hasConceptScore W1579863504C2777389519 @default.
• W1579863504 hasConceptScore W1579863504C2777802072 @default.
• W1579863504 hasConceptScore W1579863504C2777910003 @default.
• W1579863504 hasConceptScore W1579863504C2779384505 @default.
• W1579863504 hasConceptScore W1579863504C2779429289 @default.
• W1579863504 hasConceptScore W1579863504C2779434656 @default.
• W1579863504 hasConceptScore W1579863504C2780394083 @default.
• W1579863504 hasConceptScore W1579863504C2780739268 @default.
• W1579863504 hasConceptScore W1579863504C509974204 @default.

• next